ERBB2 and neoplasm: While currently available treatment regimens continue to change, particularly with the introduction of the antibody–drug conjugate trastuzumab-deruxtecan for HER2-low expressing tumors [57], immunodetection methods serve as established tumor subclassification tools to analyze tumor cell phenotype and functional state.